• Collaboration to evaluate combination of Imugene's onCARlytics oncolytic virus and JW's Carteyva® CD19 CAR-T cell therapy in solid tumors
• Includes preclinical studies and a Phase 1 investigator-initiated trial in China
• Leverages 'mark and kill' strategy to make solid tumors targetable by CD19 CAR-T cells

Imugene Ltd (ASX:IMU) and JW Therapeutics (Shanghai) Co., LTD (HKEX:2126) have announced a co-development collaboration to evaluate the combination of Imugene's oncolytic virus CF33-CD19 (onCARlytics) and JW's Carteyva®--a CD19-directed autologous CAR-T cell therapy--for patients with advanced solid tumors. The collaboration includes preclinical in vitro and in vivo studies, followed by a Phase 1 investigator-initiated trial to be conducted exclusively in China at premier CAR-T clinical centers. The approach utilizes Imugene's CF33-CD19 virus to induce CD19 expression on tumor cells, rendering them susceptible to targeting by CD19 CAR-T therapies--a transformative 'mark and kill' strategy. This collaboration allows Imugene to validate its onCARlytics platform in combination with an approved autologous CAR-T product, leveraging JW's commercial CAR-T infrastructure and Imugene's clinical onCARlytics platform to generate preclinical and clinical data and inform further clinical development.